Why carry out this study?

Secukinumab has demonstrated sustained long-term efficacy with a favourable safety profile in various manifestations of psoriatic disease in clinical trials.

In the real world, secukinumab is prescribed for patients with chronic plaque psoriasis who may have clinical features that differ from those seen in controlled clinical trials; therefore, the collection of real-world data becomes essential in the characterisation of the patterns of secukinumab use in the everyday clinical practice where other treatment options are available.

Real-world data on the effectiveness of secukinumab in the Asia-Pacific and Middle East regions are sparse.

REALIA was a non-interventional, multicentre, prospective, parallel group study conducted to investigate effectiveness and safety of secukinumab, other biologics and conventional systemic therapies in patients with chronic plaque psoriasis in a real-world setting.

What has been learned from the study?

The findings from the REALIA study conducted in a large geographical region of Asia-Pacific and Middle East suggest that secukinumab is prescribed in patients with chronic plaque psoriasis with higher prevalence of psoriatic arthritis, more severe and longer duration of the disease, compared with patients treated with conventional systemics and other biologics.

The results confirm that secukinumab is effective and well tolerated in patients with psoriasis in a real-world setting, and these findings are in line with the clinical outcomes of secukinumab reported in clinical trials.